Genetic Signatures Limited (GSS) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

You guys can see me okay? Yes, thank you, Mike. I need to get the background. Yes, at the moment you're just fuzzy. It's okay, it works. I think so. Daniel, give us the cue. No. like just changing it now so Daniel will introduce us yeah Hello and welcome to the first half FY26 presentation for Genetic Signatures. Today we have Chair Caroline Waldron and Interim Chief Financial Officer Anne Lockwood who will take us through the call today. There is a Q&A function at the bottom of your screen so please send through any questions that you have and they'll be read out at the conclusion of the presentation. I will now hand it over to Caroline. Thank you, Daniel. Good morning, everyone, and thank you for joining us today. As Daniel said, my name is Caroline, and I'm in the room with my board colleague and managing director, Anne Lockwood, outgoing CEO, Alison Rositer, and incoming CEO, Maria Hallas. Also attending virtually are my fellow directors, Jen Harry and Mike Aker. I trust you have had the opportunity to read our first half 26 results released this morning along with the slide deck. We are here today to discuss these results and the initiatives we are currently undertaking to grow our sales in the US as well as consolidate our Australian business. You will also hear from our incoming CEO, Maria Hallas. The slide deck which has been uploaded to the ASX website is for you to peruse at your pleasure. I'm going to speak to the summary that is contained in slide number three. While the company's first half performance has been consistent with its quarterly announcement, the board and management acknowledge that our ambitious growth in US sales of our FDA approved enteric test has not had the original market penetration expected. Nevertheless, our fundamentals for the US...